Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Free Cash Flow (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Free Cash Flow readings, the most recent being -$3.1 million for Q1 2026.

  • On a quarterly basis, Free Cash Flow rose 89.08% to -$3.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$25.9 million, a 61.59% increase, with the full-year FY2025 number at -$50.9 million, up 26.13% from a year prior.
  • Free Cash Flow hit -$3.1 million in Q1 2026 for Atara Biotherapeutics, up from -$5.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$3.1 million in Q1 2026 to a low of -$85.7 million in Q1 2022.
  • Median Free Cash Flow over the past 5 years was -$29.7 million (2024), compared with a mean of -$34.5 million.
  • Biggest five-year swings in Free Cash Flow: soared 92.22% in 2024 and later crashed 145.35% in 2025.
  • Atara Biotherapeutics' Free Cash Flow stood at -$56.9 million in 2022, then rose by 11.23% to -$50.5 million in 2023, then surged by 51.38% to -$24.6 million in 2024, then skyrocketed by 76.8% to -$5.7 million in 2025, then soared by 46.06% to -$3.1 million in 2026.
  • The last three reported values for Free Cash Flow were -$3.1 million (Q1 2026), -$5.7 million (Q4 2025), and -$9.8 million (Q3 2025) per Business Quant data.